Covid: Bal Pharma launches antiviral drug Favipiravir at Rs 85/tablet

Representational image

Drug maker Bal Pharma on Monday said it has launched antiviral drug Favipiravir in the domestic market under the brand name BALflu for the treatment of COVID-19.

The Bengaluru-based company said its formulation would be available in tablet form with 400 mg strength.

Favipiravir is being used for patients with mild to moderate COVID-19 infection as it inhibits and terminates viral protein synthesis and induces lethal metagenesis of influenza virus.

BALflu is a broad spectrum formulation which can also be used in the treatment of 53 types of influenza viruses, including seasonal strains such as ebola virus, arenavirus, bunyavirus, filovirus, west nile virus and lassa virus, Bal Pharma said in a regulatory filing.

The company's product is approved by the Drug Controller General of India (DCGI) for emergency use for the treatment of COVID-19 with an recommended dosage of 1,800 mg on the first day, followed by 800 mg from day 2 to 14, it added.

Bal Pharma Managing Director Shailesh Siroya said BALflu has the efficacy to clear the virus faster by 28.7 per cent and is marketed at a very affordable price of Rs 85 per tablet so as to enable the needy patients to access this drug on time.

BALflu is made available across all the major markets in India as a prescription drug, he added.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel